Kathryn Hunter

CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib

Roberto Piva, Bruce Ruggeri, Michael Williams et al. · Blood · 2007 · 252 citations · Full text

Antiangiogenic and Antitumor Efficacy of EphA2 Receptor Antagonist

Paweł Dobrzański, Kathryn Hunter, Susan Jones‐Bolin et al. · Cancer Research · 2004 · 159 citations

CEP-32496: A Novel Orally Active BRAFV600E Inhibitor with Selective Cellular and <i>In Vivo</i> Antitumor Activity

Joyce James, Bruce Ruggeri, Robert C. Armstrong et al. · Molecular Cancer Therapeutics · 2012 · 47 citations · Full text

Tumor Biology, Active Braf Inhibitor, Novel Therapy +15

Synthesis and Biological Profile of the pan-Vascular Endothelial Growth Factor Receptor/Tyrosine Kinase with Immunoglobulin and Epidermal Growth Factor-Like Homology Domains 2 (VEGF-R/TIE-2) Inhibitor 11-(2-Methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4<i>H</i>-indazolo[5,4-a]pyrrolo[3,4-c]carbazol-4-one (CEP-11981): A Novel Oncology Therapeutic Agent

Robert L. Hudkins, Nadine C. Becknell, Allison L. Zulli et al. · Journal of Medicinal Chemistry · 2011 · 42 citations · Full text

Pharmacotherapy, Tumor Angiogenesis, Tumor Biology +16

The effects of the oral, pan-VEGF-R kinase inhibitor CEP-7055 and chemotherapy in orthotopic models of glioblastoma and colon carcinoma in mice

Susan Jones‐Bolin, Hugh Zhao, Kathryn Hunter et al. · Molecular Cancer Therapeutics · 2006 · 42 citations